1032229-33-6 Usage
Description
4-(2-Chlorophenoxy)-N-[3-[(methylamino)carbonyl]phenyl]-1-Piperidinecarboxamide is a chemical compound that functions as a stearoyl-CoA desaturase 1 (SCD1) inhibitor. It is characterized by its complex molecular structure, which includes a chlorophenoxy group and a piperidinecarboxamide moiety, among other features. 4-(2-Chlorophenoxy)-N-[3-[(methylamino)carbonyl]phenyl]-1-Piperidinecarboxamide is designed to target and inhibit the activity of the SCD1 enzyme, which plays a crucial role in lipid metabolism.
Uses
Used in Pharmaceutical Industry:
4-(2-Chlorophenoxy)-N-[3-[(methylamino)carbonyl]phenyl]-1-Piperidinecarboxamide is used as a pharmaceutical agent for the treatment of various metabolic disorders and conditions related to lipid metabolism. Its primary application is as an SCD1 inhibitor, which helps regulate the synthesis of fatty acids and the balance of lipids in the body. By inhibiting SCD1, this compound can potentially contribute to the management of obesity, diabetes, and other related health issues.
Used in Research Applications:
In addition to its pharmaceutical applications, 4-(2-Chlorophenoxy)-N-[3-[(methylamino)carbonyl]phenyl]-1-Piperidinecarboxamide is also utilized in research settings. It serves as a valuable tool for studying the role of SCD1 in lipid metabolism and its implications in various diseases. Researchers can use this compound to investigate the mechanisms by which SCD1 affects cellular processes and to explore potential therapeutic targets for the development of new treatments.
Used in Drug Development:
4-(2-Chlorophenoxy)-N-[3-[(methylamino)carbonyl]phenyl]-1-Piperidinecarboxamide is employed in the development of new drugs targeting SCD1 inhibition. Pharmaceutical companies and research institutions use this compound as a starting point for designing and optimizing novel therapeutic agents that can effectively modulate SCD1 activity. This can lead to the creation of more potent and selective SCD1 inhibitors with improved pharmacological properties and reduced side effects.
Overall, 4-(2-Chlorophenoxy)-N-[3-[(methylamino)carbonyl]phenyl]-1-Piperidinecarboxamide is a versatile compound with significant potential in the fields of pharmaceuticals, research, and drug development. Its ability to inhibit SCD1 makes it a promising candidate for the treatment of various metabolic disorders and a valuable tool for advancing our understanding of lipid metabolism and its role in disease.
Biological Activity
a939572 is a potent and orally bioavailable inhibitor of stearoyl-coa desaturase1 (scd1) with ic50 value of 37nm [1].scd is a microsomal enzyme that catalyzes the biosynthesis of monounsaturated fatty acids. one member of scd family, scd1, is regulated by dietary and hormonal factors and is proved to play an important role in lipid metabolism and body weight control. thus, scd1 is a target for the treatment of obesity and diabetes. a939572 is a synthetic inhibitor of scd1 with improved inhibitory activity and lipophilicity than its parent compound. it shows inhibition of mouse scd1 and human scd1 with ic50 values of
references
[1] xin z, zhao h, serby m d, et al. discovery of piperidine-aryl urea-based stearoyl-coa desaturase 1 inhibitors. bioorganic & medicinal chemistry letters, 2008, 18(15): 4298-4302.
Check Digit Verification of cas no
The CAS Registry Mumber 1032229-33-6 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,0,3,2,2,2 and 9 respectively; the second part has 2 digits, 3 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 1032229-33:
(9*1)+(8*0)+(7*3)+(6*2)+(5*2)+(4*2)+(3*9)+(2*3)+(1*3)=96
96 % 10 = 6
So 1032229-33-6 is a valid CAS Registry Number.
1032229-33-6Relevant articles and documents
Discovery of piperidine-aryl urea-based stearoyl-CoA desaturase 1 inhibitors
Xin, Zhili,Zhao, Hongyu,Serby, Michael D.,Liu, Bo,Liu, Mei,Szczepankiewicz, Bruce G.,Nelson, Lissa T.J.,Smith, Harriet T.,Suhar, Tom S.,Janis, Rich S.,Cao, Ning,Camp, Heidi S.,Collins, Christine A.,Sham, Hing L.,Surowy, Teresa K.,Liu, Gang
scheme or table, p. 4298 - 4302 (2009/04/06)
A series of structurally novel stearoyl-CoA desaturase1 (SCD1) inhibitors has been identified via molecular scaffold manipulation. Preliminary structure-activity relationship (SAR) studies led to the discovery of potent, and orally bioavailable piperidine-aryl urea-based SCD1 inhibitors. 4-(2-Chlorophenoxy)-N-[3-(methyl carbamoyl)phenyl]piperidine-1-carboxamide 4c exhibited robust in vivo activity with dose-dependent desaturation index lowering effects.
